Incorporating yoga as a complementary therapy to standard pharmacological treatment of migraine helps reduce the frequency and intensity of migraine and its impact on the lives of people with such condition, according to the CONTAIN* study presented at the 2019 AHS Meeting.
The novel small-molecule CGRP* receptor inhibitor ubrogepant was effective in relieving migraine pain and resolving the most bothersome migraine-associated symptom (MBS) regardless of prior triptan treatment, including in patients in whom triptans were ineffective, according to a pooled analysis of ACHIEVE I and II studies presented at AHS 2019.
Individuals who identify as sexual or gender minorities (SGM) appear to be at a higher risk of experiencing subjective cognitive decline (SCD) than individuals who identify as cisgender and heterosexual, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
Intensive glucose control for up to 72 hours was no better than standard therapy in terms of improving outcomes in hospitalized patients with hyperglycaemia and acute ischaemic stroke in the SHINE* trial, suggesting that intensive glucose control may not be useful in this setting.
Older individuals with atrial fibrillation (AF) who received direct oral anticoagulants (DOACs) upon discharge from hospital following an ischaemic stroke had better long-term function and independence and a lower risk of major adverse cardiovascular events (MACE) compared with those who received warfarin, according to findings of the observational PROSPER* study.
The use of sleep medications may be associated with the risk of dementia or Alzheimer’s disease (AD) in older adults, according to two studies presented at the recent Alzheimer’s Association International Conference (AAIC 2019).
The small-molecule CGRP* receptor inhibitor rimegepant in orally disintegrating tablet (ODT) formulation provides rapid and sustained relief from an acute migraine attack with no safety concerns compared with placebo, according to a study presented at the recent AHS 2019 Meeting.
While reducing systolic blood pressure (BP), the calcium channel blocker nilvadipine also improves cerebral blood flow (CBF) in the hippocampus of individuals with Alzheimer’s disease (AD), reveals a substudy of the NILVAD* trial, indicating that the known reduction in CBF related to AD may be reversed with antihypertensive treatment.
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.